Trial Condition(s):

Contrast medium

Study on the risk of allergy-like reactions after intra-arterial or intra-venous injection of the marketed X-ray contrast medium Iopromid (UVIA)

Bayer Identifier:

19677

ClinicalTrials.gov Identifier:

NCT03622801

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Iopromide (trade name is Ultravist) is on the market for more than 30 years and has been used more than 250 million times as X-ray contrast medium for patients. It is known that Iopromide may cause allergy-like reactions after being injected. With this study researchers want to find out, if the risk of severe allergy-like reactions is lower, when Iopromide will be injected into an artery, compared to the risk after an injection of Iopromid into a vein. To find this out data from four trials on Iopromide that are already completed will be combined and newly analyzed. The database used for this analysis will contain data from more than 150,000 patients.

Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
133331
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Ultravist (Iopromide, BAY86-4877)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Many Locations

Many Locations, Germany

Status
Completed
 

Trial Design